Objective: This retrospective study aimed at discussing epidemioclinical criteria and therapeutic results of persistent gestational trophoblastic disease (PGTD) throughout a series of 20 patients treated between 2008 and 2015. Patients and methods: We reviewed the epidemioclinical records of all the patients. After aspiration, pretherapeutic work-up, and hebdomadary dosage of plasmatic HCG, patients were divided into three prognostic groups according to the GustaveRoussy Institute (IGR) classification (Hydatidiform mole, Low-risk tumors, and High-risk tumors). They were treated with different chemotherapy protocols: monodrug Methotrexate (MTX) therapy, AE protocol (Actinomycin and Etoposid), and APE protocol (Actinomycin, Etoposid, and Cisplatinum) adapted to each group. Results: The mean age was 32 years (range: 20 to 49). Metrorrhagia and pelvic pain were the most frequent symptoms. There were 20 cases of PGTD (mole retention: three cases, invasive moles: 13 cases and choriocarcinoma: 4 cases). All the evaluable patients (18 patients) were cured with the first-line chemotherapy or after salvage chemotherapy in patients with considerable risk for the disease who showed a resistance to monodrug Methotrexate therapy. We recorded one toxic death with APE protocol. Conclusions: The epidemioclinical criteria did not have any particularity. We confirmed the effectiveness of chemotherapy in PTGD. However, if we consider efficacy/toxicity ratio and the recent data of the WHO classification modified by FIGO, therapeutic deescalate may be justified at least in patients with good observance.